LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 301

Search options

  1. Book: Atlas of wide-field retinal angiography and imaging

    Kozak, Igor / Arevalo, J. Fernando

    2016  

    Keywords RETINAL ANGIOGRAPHY ; retinal imaging ; ophthalmology ; retinal disease ; Wide-Field Retinal Angiography
    Language English
    Size XVI, 259 S. : zahlr. Ill., 254 mm x 178 mm
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book
    HBZ-ID HT018960764
    ISBN 978-3-319-17863-9 ; 3-319-17863-6 ; 978-3-319-17864-6 ; 3-319-17864-4
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Book: Uveitis in the developing world

    Arevalo, J. Fernando

    (International ophthalmology clinics ; 50,2)

    2010  

    Author's details ed. by J. Fernando Arevalo
    Series title International ophthalmology clinics ; 50,2
    Collection
    Language English
    Size XVI, 234 S. : Ill.
    Publisher Lippincott Williams & Wilkins
    Publishing place Philadelphia, Pa
    Publishing country United States
    Document type Book
    HBZ-ID HT016430444
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Book ; Online ; E-Book: Retinal and choroidal imaging in systemic diseases

    Chhablani, Jay / Majumder, Parthopratim Dutta / Arevalo, J. Fernando

    2018  

    Author's details Jay Chhablani, Parthopratim Dutta Majumder, J. Fernando Arevalo editors
    Keywords Medicine ; Ophthalmology
    Subject code 617.7
    Language English
    Size 1 Online-Ressource (xxxii, 284 Seiten), Illustrationen
    Publisher Springer
    Publishing place Singapore
    Publishing country Singapore
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019582938
    ISBN 978-981-10-5461-7 ; 9789811054594 ; 981-10-5461-4 ; 9811054592
    DOI 10.1007/978-981-10-5461-7
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  4. Book: Retinal angiography and optical coherence tomography

    Arevalo, J. Fernando

    2009  

    Author's details ed. by J. Fernando Arevalo
    Language English
    Size XVIII, 471 S. : zahlr. Ill.
    Publisher Springer Science+Business Media
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT015873878
    ISBN 978-0-387-68986-9 ; 0-387-68986-9 ; 9780387689876 ; 0387689877
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  5. Article: Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023.

    Arevalo, J Fernando / Beatson, Bradley

    International journal of retina and vitreous

    2023  Volume 9, Issue 1, Page(s) 29

    Abstract: The treatment of proliferative diabetic retinopathy (PDR) has evolved significantly since the initial use of panretinal photocoagulation as a treatment in the 1950s. Vascular endothelial growth factor inhibitors have provided an effective alternative ... ...

    Abstract The treatment of proliferative diabetic retinopathy (PDR) has evolved significantly since the initial use of panretinal photocoagulation as a treatment in the 1950s. Vascular endothelial growth factor inhibitors have provided an effective alternative without the risk of peripheral vision loss. Despite this, the risk of complications requiring surgical intervention in PDR remains high. Intravitreal bevacizumab has shown promise as a preoperative adjuvant to vitrectomy for PDR complications, albeit with a purported risk for tractional retinal detachment (TRD) progression in eyes with significant fibrous proliferation. Here we will discuss anti-VEGF agent use in PDR and its role in surgical intervention for PDR complications including TRD.
    Language English
    Publishing date 2023-04-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2836254-8
    ISSN 2056-9920
    ISSN 2056-9920
    DOI 10.1186/s40942-023-00467-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Surgery for Infectious Retinitis - When Medical Therapy Is Not Sufficient: The Moacyr E. Alvaro Pan-American Lecture 2023.

    Arevalo, J Fernando / Beatson, Bradley

    Ocular immunology and inflammation

    2023  , Page(s) 1–9

    Abstract: Background: Viral retinitis composes a group of infectious ocular diseases with poor prognoses. With the advent of antivirals and HAART, the treatment of these diseases has evolved and ocular outcomes have improved. However, even with prompt medical ... ...

    Abstract Background: Viral retinitis composes a group of infectious ocular diseases with poor prognoses. With the advent of antivirals and HAART, the treatment of these diseases has evolved and ocular outcomes have improved. However, even with prompt medical treatment, a significant number of patients will experience complications that require surgical intervention. While there has been an abundance of research examining the medical treatment of CMV retinitis and acute retinal necrosis, the research examining surgical outcomes of complications such as retinitis-associated retinal detachment is comparatively limited.
    Methods: Literature review.
    Results: In this review, we discuss the current literature examining treatment of CMV retinitis and acute retinal necrosis, with a focus on surgical management of complications such as retinal detachment.
    Conclusions: Despite significant improvements in the medical treatment of CMV retinitis and ARN over the last three decades, vision-threatening complications such as retinal detachment are relatively common and require surgical management via PPV, laser photocoagulation, and intraocular gas or silicone oil tamponade.
    Language English
    Publishing date 2023-02-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 1193873-0
    ISSN 1744-5078 ; 0927-3948
    ISSN (online) 1744-5078
    ISSN 0927-3948
    DOI 10.1080/09273948.2023.2174883
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Safe Viewing of Solar Eclipses.

    Bressler, Neil M / Kong, Jun / Arévalo, J Fernando

    JAMA

    2024  Volume 331, Issue 13, Page(s) 1162

    MeSH term(s) Sunlight
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Patient Education Handout ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2024.1302
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-related Macular Degeneration: An Updated Meta-analysis.

    Roshanshad, Amirhossein / Moosavi, Seyed Ali / Arevalo, J Fernando

    Ophthalmic research

    2024  

    Abstract: Introduction: Anti-vascular endothelial growth factor (anti-VEGF) agents have a variable effect on patients with age-related macular degeneration (AMD) that has been attributed to several causes, including genetic factors. We evaluated the effects of ... ...

    Abstract Introduction: Anti-vascular endothelial growth factor (anti-VEGF) agents have a variable effect on patients with age-related macular degeneration (AMD) that has been attributed to several causes, including genetic factors. We evaluated the effects of Complement Factor H (CFH) rs1061170/Y402H polymorphism on the response to anti-VEGF therapy among AMD patients.
    Methods: PubMed, Scopus, EMBASE, Web of Science, and Google Scholar were used for a literature search. Pooled odds ratios (ORs) and their 95% confidence intervals (CIs) were estimated to assess the effects of CFH Y402H polymorphism on the response to anti-VEGF therapy in AMD. I2 was used to present the amount of heterogeneity. We used STATA version 14.0 software.
    Results: Twenty-five papers reporting data for 4681 patients were included in this study. Better response to anti-VEGF therapy was seen in T over C (OR=1.25, 95%CI=1.04-1.50), TT over CC (OR=1.60, 95%CI=1.06-2.4), and TT+TC over CC (OR=1.68, 95%CI=1.23-2.28) genotypes. There was no significant difference in three other genetic models (TT vs. TC, TT vs. TC+CC, TC vs. TT+CC). In Asians, no significant difference was observed in all six genetic models. Ranibizumab and bevacizumab had similar efficacy; however, conbercept was more effective in homozygous genotypes. The literature indicated that TT and TC genotypes and T allele were associated with a better functional response, while the CC genotype and C alleles had a better anatomical response. The combination of risk alleles in ARMS2 A69S (rs10490924), VEGF-A (rs699947), and VEGF-A (rs833069) with Y420H is a predictor of non-respondents.
    Conclusion: In patients with AMD, the CFH Y402H is a predictor of the response to anti-VEGF agents and should be considered in the treatment plan.
    Language English
    Publishing date 2024-05-16
    Publishing country Switzerland
    Document type Systematic Review
    ZDB-ID 205708-6
    ISSN 1423-0259 ; 0030-3747
    ISSN (online) 1423-0259
    ISSN 0030-3747
    DOI 10.1159/000539377
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Treating patients with geographic atrophy: are we there yet?

    Antonio-Aguirre, Bani / Arevalo, J Fernando

    International journal of retina and vitreous

    2023  Volume 9, Issue 1, Page(s) 72

    Abstract: Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older. The development of GA is influenced by various modifiable and non-modifiable risk factors, including ...

    Abstract Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older. The development of GA is influenced by various modifiable and non-modifiable risk factors, including age, smoking, and specific genetic variants, particularly those related to the complement system regulators. Given the multifactorial and complex nature of GA, several treatment approaches have been explored, such as complement inhibition, gene therapy, and cell therapy. The recent approval by the Food and Drug Administration of pegcetacoplan, a complement C3 inhibitor, marks a significant breakthrough as the first approved treatment for GA. Furthermore, numerous interventions are currently in phase II or III trials, alongside this groundbreaking development. In light of these advancements, this review provides a comprehensive overview of GA, encompassing risk factors, prevalence, genetic associations, and imaging characteristics. Additionally, it delves into the current landscape of GA treatment, emphasizing the latest progress and future considerations. The goal of starting this discussion is to ultimately identify the most suitable candidates for each therapy, highlight the importance of tailoring treatments to individual cases, and continue monitoring the long-term implications of these emerging interventions.
    Language English
    Publishing date 2023-11-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2836254-8
    ISSN 2056-9920
    ISSN 2056-9920
    DOI 10.1186/s40942-023-00493-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: From the Hypotheses to Clinical Evidence in Retinal Therapy.

    Beatson, Bradley / Arevalo, J Fernando

    Journal of ophthalmic & vision research

    2021  Volume 16, Issue 2, Page(s) 287–290

    Abstract: The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization ... ...

    Abstract The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will review the literature and investigative developments on the use of IVB as a preoperative adjuvant to vitrectomy in severe PDR, specifically focusing on its ability to reduce intra- and postoperative complications and its risk for progression or development of traction retinal detachment. In particular, this review will highlight the natural progression of evidence from case series and observations to prospective, randomized clinical trials.
    Language English
    Publishing date 2021-04-29
    Publishing country India
    Document type Journal Article
    ISSN 2008-2010
    ISSN 2008-2010
    DOI 10.18502/jovr.v16i2.9092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top